256 related articles for article (PubMed ID: 18185489)
21. Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA).
Henriksson R; Capala J; Michanek A; Lindahl SA; Salford LG; Franzén L; Blomquist E; Westlin JE; Bergenheim AT;
Radiother Oncol; 2008 Aug; 88(2):183-91. PubMed ID: 18336940
[TBL] [Abstract][Full Text] [Related]
22. Current practices and future directions of therapeutic strategy in glioblastoma: survival benefit and indication of BNCT.
Matsumura A; Yamamoto T; Tsurubuchi T; Matsuda M; Shirakawa M; Nakai K; Endo K; Tokuue K; Tsuboi K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S12-4. PubMed ID: 19375923
[TBL] [Abstract][Full Text] [Related]
23. Glioblastoma in the elderly: current and future trends.
Brandes AA; Compostella A; Blatt V; Tosoni A
Crit Rev Oncol Hematol; 2006 Dec; 60(3):256-66. PubMed ID: 17027278
[TBL] [Abstract][Full Text] [Related]
24. Present and potential future issues in glioblastoma treatment.
Lefranc F; Sadeghi N; Camby I; Metens T; Dewitte O; Kiss R
Expert Rev Anticancer Ther; 2006 May; 6(5):719-32. PubMed ID: 16759163
[TBL] [Abstract][Full Text] [Related]
25. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma.
Nieder C; Astner ST; Mehta MP; Grosu AL; Molls M
Am J Clin Oncol; 2008 Jun; 31(3):300-5. PubMed ID: 18525311
[TBL] [Abstract][Full Text] [Related]
26. Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme.
Choi J; Kim G; Cho SB; Im HJ
J Nanobiotechnology; 2020 Sep; 18(1):122. PubMed ID: 32883290
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
28. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
Grabenbauer GG; Gerber KD; Ganslandt O; Richter A; Klautke G; Birkmann J; Meyer M
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):164-9. PubMed ID: 19695435
[TBL] [Abstract][Full Text] [Related]
29. [Significance of the combined use of radiosensitizing agents on radiotherapy of malignant encephaloma].
Hoshino T
Rinsho Hoshasen; 1968 Nov; 13(11):885-91. PubMed ID: 4304555
[No Abstract] [Full Text] [Related]
30. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
31. Brain metastases: current management and new developments.
Soffietti R; Rudà R; Trevisan E
Curr Opin Oncol; 2008 Nov; 20(6):676-84. PubMed ID: 18841050
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy for brain metastases: improving the therapeutic ratio.
Patel RR; Mehta MP
Clin Cancer Res; 2007 Mar; 13(6):1675-83. PubMed ID: 17363520
[TBL] [Abstract][Full Text] [Related]
33. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
34. Dose distribution and clinical response of glioblastoma treated with boron neutron capture therapy.
Matsuda M; Yamamoto T; Kumada H; Nakai K; Shirakawa M; Tsurubuchi T; Matsumura A
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S19-21. PubMed ID: 19375933
[TBL] [Abstract][Full Text] [Related]
35. Editorial: Hypoxic cell radiosensitizers.
Belli JA; Hellman S
N Engl J Med; 1976 Jun; 294(25):1399-400. PubMed ID: 177876
[No Abstract] [Full Text] [Related]
36. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches.
Gilbert MR
Semin Oncol; 2011 Dec; 38 Suppl 4():S21-33. PubMed ID: 22078645
[TBL] [Abstract][Full Text] [Related]
37. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
38. Biological factors and therapeutic modulation in brain tumor radiotherapy.
De Santis M; Caiazza A; Simili A
Rays; 2002; 27(3):201-3. PubMed ID: 12696250
[TBL] [Abstract][Full Text] [Related]
39. Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation.
Yanagihara TK; Saadatmand HJ; Wang TJ
J Neurooncol; 2016 Dec; 130(3):397-411. PubMed ID: 27632018
[TBL] [Abstract][Full Text] [Related]
40. Novel radiosensitizers for tumors of the central nervous system.
Mehta MP; Suh JH
Curr Opin Investig Drugs; 2004 Dec; 5(12):1284-91. PubMed ID: 15648950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
